Loading…
Glowface was warned for introducing unapproved new drugs and misbranded injectable botulinum toxin products into interstate commerce through its website (www.glowface.store) in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The company failed to obtain FDA approval for these drug products and did not ensure proper drug labeling, exposing consumers to significant risks including product contamination, counterfeit goods, inconsistent active ingredient amounts, and serious health complications from injectable administration such as septicemia or sepsis. The FDA requested immediate cessation of unapproved and misbranded drug sales to protect public health.